Megakaryocyte-restricted MYH9 inactivation dramatically affects hemostasis while preserving platelet aggregation and...

Area of Science:

• Hematology
• Molecular Biology
• Cell Biology

Background:

• Mutations in the MYH9 gene cause bleeding disorders with macrothrombocytopenia.
• Nonmuscle myosin IIA is essential for cellular contractile functions.

Purpose of the Study:

• To investigate the role of nonmuscle myosin IIA in platelet function and hemostasis.
• To elucidate the pathological mechanisms of MYH9-related bleeding disorders.

Main Methods:

• Generation of MYH9-deficient mice (MYH9Delta) specifically in megakaryocytes.
• Assessment of platelet count, bleeding time, clot retraction, aggregation, and secretion.
• Analysis of integrin signaling, lamellipodia extension, and thrombus formation under flow conditions.
• In vivo evaluation of thrombus stability following arterial injury.

Main Results:

• MYH9Delta mice exhibited macrothrombocytopenia, prolonged bleeding times, and absent clot retraction.
• Platelet aggregation and secretion were largely preserved, but initial platelet contraction was absent.
• Integrin outside-in signaling, including integrin beta3 phosphorylation, was impaired.
• Thrombus growth, organization, and stability were significantly reduced in MYH9Delta mice.

Conclusions:

• Nonmuscle myosin IIA is essential for platelet contractile function, outside-in signaling, and proper thrombus formation.
• While dispensable for suspension aggregation/secretion, myosin plays a critical role in platelet hemostatic functions.
• These findings explain the severe hemostatic defects observed in MYH9-related bleeding disorders.